^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Progesterone receptor agonist

    Related drugs:
    3d
    CoCo3 - Comprehensive Health Effects of Combined Contraceptives: a 12-month randomized, controlled, open-label trial comparing E4+DRSP, EE 20?g+DRSP and DRSP-only (2025-523359-71-00)
    P4, N=156, Not yet recruiting, Pohjois-Pohjanmaan hyvinvointialue, University Of Oulu
    New P4 trial
    5d
    Role of Estrogen on Skeletal Outcomes in FHA (clinicaltrials.gov)
    P2, N=150, Recruiting, University of Virginia | Initiation date: Jul 2025 --> Oct 2025
    Trial initiation date
    |
    IGF1 (Insulin-like growth factor 1)
    5d
    Hormonal Influences on Inflammatory Bowel Diseases (clinicaltrials.gov)
    P=N/A, N=50, Completed, University of Utah | Not yet recruiting --> Completed | N=200 --> 50 | Trial completion date: Mar 2027 --> Dec 2025 | Trial primary completion date: Aug 2026 --> Dec 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    6d
    Invasive ductal and lobular carcinoma and receptor status in the genetic context of breast cancer. (PubMed, Sci Rep)
    and be estrogen receptor positive [p < 0.001] progesterone status positive [p < 0.001] and HER2 negative [p = 0.043]...This can help clinicians adapt when counseling these patients. Furthermore, ILC keeps its distinctive characteristics independent of the genetic backdrop.
    Journal • BRCA Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • BRCA2 (Breast cancer 2, early onset) • PALB2 (Partner and localizer of BRCA2) • PMS2 (PMS1 protein homolog 2) • CDH1 (Cadherin 1) • CHEK2 (Checkpoint kinase 2) • EPCAM (Epithelial cell adhesion molecule)
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    7d
    NIRO: Norethindrone Impact on Receptiva Outcomes (clinicaltrials.gov)
    P=N/A, N=99, Completed, Inception Fertility Research Institute, LLC | Active, not recruiting --> Completed | N=700 --> 99 | Trial completion date: Jul 2026 --> Dec 2025
    Trial completion • Enrollment change • Trial completion date
    |
    BCL6 (B-cell CLL/lymphoma 6)
    |
    leuprolide acetate for depot suspension
    7d
    Progesterone Primed Protocol Versus GnRH Antagonist in With PCO Undergoing ICSI (clinicaltrials.gov)
    P2/3, N=200, Completed, Beni-Suef University | Not yet recruiting --> Completed | Trial completion date: Sep 2023 --> Apr 2026 | Trial primary completion date: Sep 2023 --> Mar 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    Cetrotide (cetrorelix)
    8d
    Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients (clinicaltrials.gov)
    P3, N=227, Active, not recruiting, Alliance for Clinical Trials in Oncology | Recruiting --> Active, not recruiting | N=360 --> 227
    Enrollment closed • Enrollment change
    |
    megestrol • olanzapine
    9d
    RESToRE: Risk Evaluation and Screening to Tailor Prevention and Reduce the Incidence of Endometrial Cancer (clinicaltrials.gov)
    P4, N=96, Completed, University of British Columbia | Active, not recruiting --> Completed | N=250 --> 96
    Trial completion • Enrollment change
    |
    medroxyprogesterone
    9d
    Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG) (clinicaltrials.gov)
    P1, N=24, Completed, Atea Pharmaceuticals, Inc. | Not yet recruiting --> Completed
    Trial completion
    9d
    Kuwa Free! - Live Free! (clinicaltrials.gov)
    P=N/A, N=700, Recruiting, University of Alabama at Birmingham | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    9d
    Estradiol 8 vs 12 mg for Endometrial Preparation in HRT-FET (clinicaltrials.gov)
    P4, N=850, Completed, Cairo University
    New P4 trial
    13d
    SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer (clinicaltrials.gov)
    P=N/A, N=82, Not yet recruiting, Hospital Universitari de Bellvitge | Trial completion date: Dec 2026 --> Sep 2028 | Initiation date: May 2026 --> Sep 2026 | Trial primary completion date: Jun 2026 --> May 2027
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    TP53 wild-type
    |
    megestrol